Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is a severely debilitating disease of high and growing proportions. Hypercholesterolaemia is a key risk factor in sporadic Alzheimer's disease that links metabolic disorders (diabetes, obesity and atherosclerosis) with this pathology. Hypercholesterolaemia is associated with increased levels of immunoglobulin G against oxidized lipoproteins. Patients with Alzheimer's disease produce autoantibodies against non-brain antigens and specific receptors for the constant Fc region of immunoglobulin G have been found in vulnerable neuronal subpopulations. Here, we focused on the potential role of Fc receptors as pathological players driving hypercholesterolaemia to Alzheimer's disease. In a well-established model of hypercholesterolaemia, the apolipoprotein E knockout mouse, we report increased brain levels of immunoglobulin G and upregulation of activating Fc receptors, predominantly of type IV, in neurons susceptible to amyloid β accumulation. In these mice, gene deletion of γ-chain, the common subunit of activating Fc receptors, prevents learning and memory impairments without influencing cholesterolaemia and brain and serum immunoglobulin G levels. These cognition-protective effects were associated with a reduction in synapse loss, tau hyperphosphorylation and intracellular amyloid β accumulation both in cortical and hippocampal pyramidal neurons. In vitro, activating Fc receptor engagement caused synapse loss, tau hyperphosphorylation and amyloid β deposition in primary neurons by a mechanism involving mitogen-activated protein kinases and β-site amyloid precursor protein cleaving enzyme 1. Our results represent the first demonstration that immunoglobulin G Fc receptors contribute to the development of hypercholesterolaemia-associated features of Alzheimer's disease and suggest a new potential target for slowing or preventing Alzheimer's disease in hypercholesterolaemic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
The Medial Temporal Lobe and Recognition Memory
Eichenbaum, H., Yonelinas, A. P., & Ranganath, C. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094328 · Cited by 2,580
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237 · cited 1×
“Given that a multiplicity of risk factors may be represented in hypercholesterolaemia and the fact that Alzheimer’s disease is associated with IgG overproduction and blood–brain barrier leakage, studies were performed in apolipoprotein E (apoE) knockout mice, which display overt hypercholesterolaemia (Zhang et al., 19…”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 2×
“, 2004) and cleared with reduced efficiency (Mawuenyega et al., 2010) in sporadic Alzheimer’s disease, we here explored the mechanisms through which Fc R activation may lead to increased levels of cerebral amyloid b.”
BackgroundBell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., Tsui, H., Wu, P., Davidson, M. G., Alonso, M. N., et al. (2011) · Nature Medicine · doi:10.1038/nm.2353 · Cited by 1,050
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“(Gouras et al., 2000; Gyure et al., 2001; Fernandez-Vizarra et al., 2004).”
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729 · cited 3×
“, 2010) and whose expression and activity is upregulated in patients with sporadic Alzheimer’s disease (Yang et al., 2003; Li et al., 2004).”
BackgroundAltered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
Losing your nerves? Maybe it's the antibodies
Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C., & Volpe, B. T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2529 · Cited by 247
Chronic activation of ERK and neurodegenerative diseases
Colucci‐D'Amato, L., Perrone‐Capano, C., & di Porzio, U. (2003) · BioEssays · doi:10.1002/bies.10355 · Cited by 195 · cited 2×
“Activation of JNK and ERK pathways have been implicated in synaptic plasticity (Curtis and Finkbeiner, 1999), amyloid b production and tau phosphorylation (Sato et al., 2002; Colucci-D’Amato et al., 2003) and are known to be involved in Fc R signalling (Song et al.”
BackgroundApoE Deficiency Compromises the Blood Brain Barrier Especially After Injury
Methia, N., André, P., Hafezi-Moghadam, A., Economopoulos, M., Thomas, K. L., & Wagner, D. D. (2001) · Molecular Medicine · doi:10.1007/bf03401973 · Cited by 150 · cited 2×
“Loss of integrity of the blood–brain barrier, as well as IgG deposits and/or Fc R expression, are also associated with Alzheimer’s disease risk factors other than ageing, namely atherosclerosis, obesity and diabetes (Methia et al., 2001; Kuang et al., 2004; Hafezi-Moghadam et al., 2007; Bake et al., 2009; Diamond et a…”
BackgroundApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage
Hafezi-Moghadam, A., Thomas, K. L., & Wagner, D. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00563.2005 · Cited by 149 · cited 3×
“Our hypothesis that IgG is involved in the onset of certain sporadic forms of Alzheimer’s disease is consistent with recent data suggesting that factors that induce weakening of the blood–brain barrier may be causally related to neurodegenerative disease; since this barrier gets leaky during normal ageing (Hafezi-Mogh…”
BackgroundResultTurk, Z., Ljubic, S., Turk, N., & Benko, B. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00389-2 · Cited by 111
Antibodies to viral antigens, xenoantigens, and autoantigens in Alzheimer’s disease
Ounanian, A., Seigneurin, J. ‐., Guilbert, B., Avrameas, S., & Renverez, J. ‐. (1990) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860040510 · Cited by 58
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Doens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348
“FcγRs expressed on neurons have also been implicated in neurotoxicity and inflammation occurring directly in these cells [54,55].”
BackgroundTucsek, Z., Toth, P., Sosnowska, D., Gautam, T., Mitschelen, M., Koller, A., Szalai, G., Sonntag, W. E., Ungvari, Z., & Csiszar, A. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt177 · Cited by 328
Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195
“Additionally, neurons are responsive to extracellular IgG by up-regulating Fc R (44).”
BackgroundFrom the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187
Metadata
- Authors
- Fernandez-Vizarra, P., Lopez-Franco, O., Mallavia, B., Higuera-Matas, A., Lopez-Parra, V., Ortiz-Munoz, G., Ambrosio, E., Egido, J., Almeida, O. F. X., & Gomez-Guerrero, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 135
- Issue
- 9
- Pages
- 2826-2837
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2124824920
- Cited by
- 42
- References
- 19
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.